Search
DPCPX
go.drugbank.com/drugs/DB12946InvestigationalCPX has been used in trials studying the treatment of Cystic Fibrosis.
Categories: Purinergic P1 Receptor AntagonistsBinodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective d...
Categories: Purinergic P1 Receptor AgonistsIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Categories: Purinergic P1 Receptor AgonistsClopidogrel
go.drugbank.com/drugs/DB00758ApprovedInvestigationalClopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalAminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTicagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigationalTicagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilin...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTheophylline
go.drugbank.com/drugs/DB00277ApprovedInvestigationalA methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine recep...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesLosartan
go.drugbank.com/drugs/DB00678ApprovedInvestigationalLosartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associate...
Mixtures: LORZAAR PL FORTE100/12.5MGCategories: P-glycoprotein inhibitors, P-glycoprotein substrates